2011-2019年美国毒物中心报告的6岁以下儿童直接Xa因子抑制剂急性非故意单药暴露
该研究回顾性分析2011年1月1日至2019年12月31日美国国家毒物数据系统®中年龄<6岁、单药非故意摄入直接Xa因子抑制剂的病例,共纳入744例。350例居家管理病例中346例无效应、4例轻微效应;394例在医疗机构治疗/评估的病例中337例(85.5%)无效应、33例(8.4%)轻微效应、22例(5.6%)中度效应、2例(0.5%)重度效应。未报告出血相关临床效应,122例接受活性炭治疗。作者结论认为无症状、非故意、单药暴露的<6岁儿童可能不易发生临床显著出血。
要点
- 共744例<6岁儿童单药非故意摄入直接Xa因子抑制剂,无出血相关临床效应编码。
- 350例居家管理病例中346例无效应、4例轻微效应。
- 394例在医疗机构治疗/评估的病例中337例(85.5%)无效应、33例(8.4%)轻微效应、22例(5.6%)中度效应、2例(0.5%)重度效应。
- 122例患者接受活性炭治疗。
- 2例重度效应中1例涉及摄入最多500 mg利伐沙班并伴实验室凝血异常,但出血未被编码为临床效应。
适用人群与场景
- 年龄<6岁、单药、非故意摄入直接Xa因子抑制剂的儿童。
- 排除医疗结局编码为无关效应、确认非暴露、未随访(无毒/轻微毒性)、无法随访(潜在毒性)或未提供结局的病例。
处置流程与药物剂量
- 122例患者接受了活性炭治疗。
红旗征与不能漏的情况
- 2例重度效应中1例涉及摄入最多500 mg利伐沙班并伴实验室凝血异常,但出血未被编码为临床效应。
研究设计与关键结果
- 回顾性分析2011年1月1日至2019年12月31日美国国家毒物数据系统®报告的病例,共744例符合纳入标准。
- 350例居家管理病例中346例无效应、4例轻微效应。
- 394例在医疗机构治疗/评估的病例中337例(85.5%)无效应、33例(8.4%)轻微效应、22例(5.6%)中度效应、2例(0.5%)重度效应。
- 未报告出血相关临床效应;122例患者接受活性炭治疗。
- 2例重度效应中1例涉及摄入最多500 mg利伐沙班并伴实验室凝血异常,但出血未被编码为临床效应。
证据类型、等级与局限
- 证据类型:回顾性审查美国国家毒物数据系统®报告的病例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,无症状、非故意、单药暴露于Xa因子抑制剂的<6岁患者可能不易发生临床显著出血。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Direct factor Xa inhibitors are widely used anticoagulants. Safety in adults is well studied, however limited data exist for pediatric exposures. The objective of this study is to describe referral patterns, clinical outcomes, and treatment modalities for unintentional pediatric single-substance ingestion of factor Xa inhibitors as reported to the National Poison Data System®.
METHODS: This is a retrospective review of cases reported to the National Poison Data System® from January 1, 2011 to December 31, 2019. Inclusion criteria were age <6 years with single-substance, unintentional ingestion of a direct factor Xa inhibitor. Cases were excluded if the medical outcome was coded as unrelated effect, confirmed non-exposure, not followed (non-toxic/minimal toxicity), unable to follow (potentially toxic), or outcome not provided. Data abstracted included medical outcomes, level of care, clinical effects, and therapies.
RESULTS: A total of 744 cases met inclusion criteria. Among 350 cases managed at home, outcomes included 346 cases with "no effect" and four cases with "minor effect". Among 394 cases treated/evaluated at a healthcare facility, reported medical outcomes included 337 (85.5%) cases with "no effect", 33 (8.4%) with "minor effect", 22 (5.6%) with "moderate effect", and two (0.5%) with "major effect". No clinical effects related to bleeding were reported. One hundred twenty-two patients received activated charcoal. One of the two cases with major effect involved ingestion of up to 500 mg rivaroxaban with laboratory coagulopathy, but bleeding was not coded as a clinical effect.
DISCUSSION: In this cohort of patients less than six years of age with acute, unintentional single-substance ingestion of direct factor Xa inhibitors, no cases had bleeding coded as a clinical effect. These findings are consistent with the previously described low toxicity profile of acute ingestions of these medications in children.
CONCLUSIONS: These data suggest that asymptomatic, unintentional, single substance exposures to factor Xa inhibitors in patients <6 years of age are unlikely to develop clinically significant bleeding.
参考来源
- Kolbeck M, Regan D, Hodgman M, et al. Acute unintentional single-substance pediatric exposures to direct factor Xa inhibitors reported to US Poison Centers, 2011-2019. Clin Toxicol (Phila). 2026. PMID: 41837900. doi:10.1080/15563650.2026.2634753
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。